This morning, Cellectar Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CLR 131 for the treatment of neuroblastoma.
CLR 131 is the company’s lead Phospholipid Drug Conjugate (PDC) product candidate, and is the first potential therapy that would use a PDC tumor-targeting delivery platform to deliver a cytotoxic radioisotope (iodine-131) directly to the tumor cells.
Read the full article at: http://www.raredr.com/news/clr131-orphan-drug-designation